Sleep Deprivation and Plasma Biomarkers for Alzheimer’s Disease

Authors: Martin Olsson, MD¹,²,³,⁴; Johan Ärlig, MD¹,²,³; Jan Hedner, MD, PhD³,⁴; Kaj Blennow, MD, PhD¹,²; Henrik Zetterberg, MD, PhD¹,²,⁵,⁶.

*Corresponding author: Martin Olsson, MD, Sahlgrenska University Hospital

Contact information:
E-mail: martin.v.olsson@vgregion.se
Address and Postal code: Neurochemistry, House V, Sahlgrenska University Hospital, SE-431 80, Mölndal
Telephone: (0046) 733161657, Fax: (0046) 031 34 32 426

Authors’ affiliations:
¹Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
²Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, University of Gothenburg, Sahlgrenska University Hospital, Mölndal, Sweden
³Center for Sleep and Vigilance Disorders, Department of Internal medicine, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden
⁴Sleep Laboratory, Pulmonary Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
⁵Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, UK
⁶UK Dementia Research Institute at UCL, London, UK

Authors’ contributions:
Zetterberg and Olsson had full access to the data in the study and take full responsibility of the accuracy of data analysis and the integrity of the data.

Study concept and design: Olsson, Ärlig, Hedner, Blennow, Zetterberg
Obtained funding: Hedner, Blennow, Zetterberg.
Study supervision: Hedner, Blennow, Zetterberg.
Data acquisition, analysis and/or interpretation: Ärlig, Olsson, Hedner, Blennow, Zetterberg.
Statistical analysis: Olsson, Zetterberg.
Drafting of the manuscript: Olsson, Zetterberg.
Manuscript revision for critical intellectual content: All authors
To the editor

Studies suggest that sleep is important for brain-to-blood clearance of several Alzheimer’s disease (AD)-associated proteins, potentially through the glymphatic system (1). Human data have shown a correlation between total sleep deprivation and an increase of CNS-derived biomarkers in cerebrospinal fluid (2). Our group recently published data from an experiment where 13 healthy adults were subjected to partial sleep deprivation (PSD) (5 consecutive nights with 4 hours of sleep) (3). This intervention did not affect CSF biomarkers associated with AD. We have now performed a follow up analysis of plasma from the same experiment showing unaltered concentrations of amyloid β 40, amyloid β 42, tau and neurofilament light (Table).

The interpretation of the current findings is not obvious; a negative result and a small sample size introduces a risk of a type two error. However, our data suggests that a more “clinically relevant” sleep deprivation protocol does not produce a profound change in CNS protein dynamics, as protein transport from the interstitial space or CSF to plasma does not seem to be affected. Neither CSF nor plasma mirrors the interstitial space fluid chemistry perfectly but has a useable correlation (4).

It is important to emphasise that we have not examined CNS clearance of these AD-related proteins in older adults at increased risk of AD. Our PSG data suggest that a young and healthy brain responds to PSD so that the duration of SWS/NREM stage 3 is maintained, which in turn suggesting that SWS is the sleep phase during which the glymphatic clearance system is most active. This could protect from build-up of potentially neurotoxic proteins and metabolites during the times of PSD that people so often experience during normal life. The situation could be different in the aging brain with a diminishing SWS potion of normal sleep. Further studies are needed to clarify when, or if, sleep becomes a limiting factor for protein clearance from the brain.

**Keywords** Alzheimer disease, amyloid beta, tau, neurofilament light, sleep deprivation.

**References**


Plasma biomarker data

Baseline (CS) vs PSD

<table>
<thead>
<tr>
<th>Variable</th>
<th>Baseline (CS) (N=13)</th>
<th>Partial Sleep Deprivation (N=13)</th>
<th>P Value</th>
<th>Prolonged PSD (N=4)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Plasma value</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aβ40, pg/mL</td>
<td>272.4 (28.2)</td>
<td>276.3 (26.2)</td>
<td>0.55</td>
<td>274.8 (37.0)</td>
</tr>
<tr>
<td>Aβ42, pg/mL</td>
<td>14.3 (2.2)</td>
<td>14.5 (2.4)</td>
<td>0.70</td>
<td>14.8 (2.1)</td>
</tr>
<tr>
<td>Tau, pg/mL</td>
<td>2.8 (1.1)</td>
<td>3.0 (1.3)</td>
<td>0.28</td>
<td>3.0 (0.6)</td>
</tr>
<tr>
<td>NfL, pg/mL</td>
<td>6.1 (5.7)</td>
<td>5.5 (4.1)</td>
<td>0.42</td>
<td>7.5 (4.2)</td>
</tr>
</tbody>
</table>

Abbreviations: CS, controlled sleep. PSD, partial sleep deprivation. Aβ, β-amyloid. NFL, neurofilament light.

P-values represent within group (the same subjects exposed to two sleep conditions) differences for the controlled sleep period samples compared with the partial sleep deprivation samples. P-values have not been calculated for the prolonged PSD group because of the small samplesize.